e. Thus, it presents a promising strategy for the treatment
of influenza A virus, particularly for severe and immunocompromised
patients115. A combination of amantadineþoseltamivir116 as well as
favirpiravirþoseltamivir117 have demonstrated enhanced drug effi-
cacy in H5N1 infected mice. Recently, combination therapy with
three antiviral drugs (amantadine, ribavirin, and oseltamivir) in
patients with severe A/H1N1 2009 (pH1N1) influenza in Korea has
reduced the 14-day mortality118. In another study, triple-combination
antiviral drug therapy showed similar pharmacokinetics to mono-drug
therapy and demonstrated increased safety in immunocompromised
patients118,119. Currently, several combination therapies based on
approved and/or new drugs are under investigation.
e. Thus, it presents a promising strategy for the treatmentof influenza A virus, particularly for severe and immunocompromisedpatients115. A combination of amantadineþoseltamivir116 as well asfavirpiravirþoseltamivir117 have demonstrated enhanced drug effi-cacy in H5N1 infected mice. Recently, combination therapy withthree antiviral drugs (amantadine, ribavirin, and oseltamivir) inpatients with severe A/H1N1 2009 (pH1N1) influenza in Korea hasreduced the 14-day mortality118. In another study, triple-combinationantiviral drug therapy showed similar pharmacokinetics to mono-drugtherapy and demonstrated increased safety in immunocompromisedpatients118,119. Currently, several combination therapies based onapproved and/or new drugs are under investigation.
การแปล กรุณารอสักครู่..